Beleggen.nl Markt MonitorMarkt Monitor

Pharming december 2020: van verborgen ruwe diamant naar schitterend juweel....an american dream!

19.892 Posts
Pagina: «« 1 ... 984 985 986 987 988 ... 995 »» | Laatste | Omlaag ↓
  1. [verwijderd] 31 december 2020 12:59
    quote:

    voda schreef op 31 december 2020 12:54:

    [...]
    :-)

    Wie het kleine niet eert, ....
    :-)

    Dank voor je niet aflatende zorg op dit forum, Hans. Zo’n stabiele factor is zeker voor dit forum van levensbelang. Ik lees je graag weer in het nieuwe jaar.

    Fijne jaarwisseling en alle goeds voor jou en de jouwen!

    G.
  2. forum rang 7 lucas D 31 december 2020 13:00
    quote:

    linke ro schreef op 31 december 2020 12:41:

    ik denk gekocht gisteren op 1.11 met 16 % heeft mooi 0,177 cent verdient
    Dat is echt knap, de laagste koers gisteren was € 1,169.:~)
  3. [verwijderd] 31 december 2020 13:02
    quote:

    Wilbar schreef op 31 december 2020 12:59:

    [...]
    O jee, de ene expert is net vertrokken of de volgende steekt de kop al op.
    Onderschat hem niet, tis vast zijn vader. Tis nu wachten op junior. Hebben we alle generaties.
  4. [verwijderd] 31 december 2020 13:02
    Een interessant bericht van Sinopharm, de chinese partner van Pharming, met dank aan Voda:
    Quote
    China approves Sinopharm Covid-19 vaccine for general use
    Rollout to begin ‘soon’ but about a million have already received injection under emergency approvals
    China’s health authorities have approved a Covid vaccine from state-owned Sinopharm for general use on the population, the government has announced.
    At a press conference in Beijing a state taskforce announced the vaccine had exceeded World Health Organization standards and would help establish effective immunity in China.

    Health officials said vulnerable groups would be prioritised ahead of the general population. Key groups have already been receiving vaccines under emergency approvals, including about a million receiving the Sinopharm vaccine.
    Zeng Yixin, deputy head of the national health commission, said it was aiming for 60-70% vaccination coverage, which was expected to establish herd immunity. “As the Chinese vaccine is proved to be safe and effective, we would like to encourage our people to participate on a voluntary and informed basis, and with consent,” he said.

    The officials did not give specific dates but said the rollout would begin “soon” at a “significantly reduced” cost.
    Zheng Zhongwei, head of the vaccine research and development working group, said the vaccine was a public good and the cost of production was “the only basis for pricing”.
    Zeng then added that the vaccine “must be provided free of charge for all people”, and state media subsequently reported that the vaccine will be free.
    Sinopharm is a state-owned pharmaceutical company with two vaccine candidates among China’s five experimental treatments in international final stage trials. Public statements about Sinopharm vaccines do not appear to clarify which of the two candidates is being discussed.
    The approval followed an announcement on Wednesday by Sinopharm that phase 3 trials had found its vaccine to be 79% effective. This followed trials conducted in the UAE reporting 86% efficacy earlier in December. The vaccines have not been trialled in China because the virus is not prevalent enough, authorities say.
    Chinese vaccine developers have not released trial data. On Thursday a health official said the Sinopharm data would be published “later” in Chinese and foreign medical journals.
    At an annual meeting of health workers on 22 December, Zhang Wenhong, head of infectious diseases at Fundan University’s Huasha hospital, said there was apprehension among Chinese people about the domestically produced vaccine, and party leaders should be vaccinated first to reassure the public. A recording of his comments spread quickly on Chinese social media before it was censored.
    Sinopharm and rival developer Sinovac have created their vaccines via the more traditional method of using an inactive virus to trigger an immune response. They are more difficult to manufacture quickly than other types and have the potential to cause an imbalanced immune response, but have shown historic success.
    Mao Junfeng, head of consumer products at China’s industry ministry, said vaccine producers had ramped up production capacity. “We believe China’s vaccine production will meet the demand for large scale vaccination, and looking ahead the ministry will follow the plans [of the central government] … and help enterprises expand production capacity and make sure a smooth production and supply chain will provide effective and accessible vaccines for the people.”
    In September the UAE was the first country outside China to approve emergency use of a Sinopharm vaccine. It has since been made available in Bahrain and shipped to Egypt, while Morocco is planning to rely on it to vaccinate 80% of its adult population. Other countries have signed on to receive the Sinovac vaccine, China’s other domestically produced frontrunner. In October China announced it was joining Covax, the international initiative aimed at ensuring equitable global access to vaccines.
    unquote

    Pharming heeft een langdurig alliantie met het China State Institute of Pharmaceutical Industry ("CSIPI"), een Sinopharm-bedrijf, voor gezamenlijke wereldwijde ontwikkeling van nieuwe producten, te beginnen met recombinante humane factor VIII voor de behandeling van hemofilie A. Preklinische ontwikkeling en productie zal plaatsvinden bij CSIPI volgens wereldwijde standaarden en worden gefinancierd door CSIPI. Klinische ontwikkeling wordt gedeeld tussen de partners, waarbij elke partner de kosten voor zijn grondgebied draagt in het kader van het partnerschap.

    Mooie opportunity voor Pharming om het vaccin van z’n Chinese partner naar Europa te halen.

    Zou een leuke klus voor BioConnection, de dochter van Pharming, kunnen zijn.

    Groeten,

    Jesse Livermore

    PS Prettige jaarwisseling voor een ieder en een gezond nieuw jaar gewenst.
  5. forum rang 4 pico bello 31 december 2020 13:03
    quote:

    keessie schreef op 31 december 2020 13:02:

    linke ro, stel U had 10000 aandelen maal 0,177 cent hebt U ongeveer 17 euro
    ?
  6. DRTVR 31 december 2020 13:04
    quote:

    keessie schreef op 31 december 2020 13:02:

    linke ro, stel U had 10000 aandelen maal 0,177 cent hebt U ongeveer 17 euro
    1770euro.
  7. forum rang 6 Kaviaar 31 december 2020 13:05
    quote:

    lucas D schreef op 31 december 2020 13:00:

    [...]

    Dat is echt knap, de laagste koers gisteren was € 1,169.:~)
    Een paar dagen daarvoor gekocht, rond €1,10 kan ook he

    En de poster bedoelde € 0,177
  8. forum rang 8 Braniek 31 december 2020 13:06
    quote:

    keessie schreef op 31 december 2020 13:02:

    linke ro, stel U had 10000 aandelen maal 0,177 cent hebt U ongeveer 17 euro
    rekenwonder? haha
  9. linke ro 31 december 2020 13:07
    Ordergegevens
    OpdrachtKoop
    Aantal1.000 stuks
    TypeLimiet
    Limiet€1,130
    Geldig t/m12-01-2021
    Huidige koers€1,270
    Tijdstip koers31-12-2020
    13:05:30
    Order ID61063987647
    StatusUitgevoerd
    Uitvoering
    Volume
    Prijs
    Tijdstip
    1.000 stuks€1,130
  10. [verwijderd] 31 december 2020 13:08
    quote:

    Belegd schreef op 31 december 2020 13:07:

    [...]
    Wat hij zegt klopt helemaal, dus van waar de vraagtekens?
    0,177 cent x10000. Get real en ga trg naar school
19.892 Posts
Pagina: «« 1 ... 984 985 986 987 988 ... 995 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.092
AB InBev 2 5.525
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.810
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.757
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.757
Aedifica 3 923
Aegon 3.258 322.942
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.895
Agfa-Gevaert 14 2.051
Ahold 3.538 74.343
Air France - KLM 1.025 35.192
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.043
Alfen 16 25.005
Allfunds Group 4 1.510
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.825
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.477
AMG 971 133.922
AMS 3 73
Amsterdam Commodities 305 6.698
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.027
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.787
Arcelor Mittal 2.034 320.836
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.328
Aroundtown SA 1 220
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.421
ASML 1.766 108.589
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 521
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.688
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.406